Skip to main content

MJFF Publications

261 - 270 of 7616 Results
Title
Year
  • Year
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • RESTRICTED
    Title: Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies
    Journal Name: Brain
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1093/brain/awad391
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms242216445
    Citation Count: 0
  • RESTRICTED
    Title: Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc, cc-by-nc
    DOI - Digital Object Identifier: 10.1126/sciadv.adi8716
    Citation Count: 6
  • RESTRICTED
    Title: Hippocampal glial inflammatory markers are differentially altered in a novel mouse model of perimenopausal cerebral amyloid angiopathy
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2023.1280218
    Citation Count: 0
  • RESTRICTED
    Title: Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29611
    Citation Count: 1
  • RESTRICTED
    Title: Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes
    Journal Name: Human Mutation
    Publisher: Hindawi Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1155/2023/8620557
    Citation Count: 0
  • RESTRICTED
    Title: Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-023-42876-1
    Citation Count: 2
  • RESTRICTED
    Title: Enduring questions in regenerative biology and the search for answers
    Journal Name: Communications Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s42003-023-05505-7
    Citation Count: 0
  • RESTRICTED
    Title: Targeting sleep and the circadian system as a novel treatment strategy for Parkinson’s disease
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s00415-023-12073-7
    Citation Count: 3
  • RESTRICTED
    Title: Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's
    Journal Name: European Journal of Neuroscience
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1111/ejn.16180
    Citation Count: 1
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.